Key Points:

• Swiss dental technology company vVardis Holding reduced its proposed U.S. IPO offering by approximately 13%, lowering the number of shares from 9.5 million to 8.3 million.
• The company now aims to raise approximately $188 million by offering shares at $21 to $24 each, implying a fully diluted market capitalization of approximately $1.4 billion at the midpoint.
• Founded in 2020, vVardis generated $50 million in revenue for the 12 months ended June 30, 2026, and plans to list on the New York Stock Exchange under the ticker VVVV.

vVardis Holding has reduced the size of its proposed U.S. initial public offering, cutting the number of shares on offer by approximately 13% while keeping its price range unchanged. The Zug-based dental technology company now aims to raise approximately $188 million, putting deal sizing and investor appetite for a differentiated healthcare business in focus ahead of its expected New York listing.

Company Background and Commercial Growth

Founded in 2020 by dentist sisters and co-CEOs Haley and Goly Abivardi, vVardis sells Curodont, a peptide-based treatment designed to arrest or reverse early-stage cavities without drilling or needles. Its flagship U.S. product, Curodont Repair Fluoride Plus, generates most of its revenue, while a fluoride-free version is sold as a medical device in parts of Europe. Apollo-managed funds became minority investors earlier this year.

Revenue reached $50 million in the 12 months ended June 30, 2026. Preliminary estimates put nine-month 2026 revenue at $47.7 million to $49.2 million, more than double the year-earlier period, while sales of the U.S. flagship product rose 112% in units. Curodont is available in more than 20,000 U.S. dental practices, supported by an exclusive distribution agreement with Henry Schein and vVardis’ own sales force.

IPO Details and Revised Offering Structure

The revised offering comprises 8.3 million shares, down from 9.5 million, at $21 to $24 per share. At the midpoint, the deal is expected to generate about $188 million, approximately 13% less than previously indicated, and imply a fully diluted market value of about $1.4 billion. vVardis plans to list on the New York Stock Exchange under ticker VVVV. Goldman Sachs, J.P. Morgan, William Blair, UBS Investment Bank and Deutsche Bank are the joint bookrunners. Pricing had been expected during the week of November 9, 2026.

U.S. IPO Market Context and Growth Opportunities

The smaller deal arrives in a selective U.S. IPO market. Through November 5, the Renaissance IPO Index had fallen 4.0% year to date, while the S&P 500 had gained 8.4%. Healthcare’s defensive characteristics may help attract interest, while Curodont offers a potential alternative to monitoring early cavities or treating them with invasive procedures. Further practice penetration and repeat orders will be central to sustaining growth.

Risks and Challenges for Investors

Risks remain material. Preliminary estimates show a net loss of $39.7 million to $41.3 million for the first nine months of 2026. The U.S. flagship is marketed under an FDA over-the-counter monograph, not a product-specific NDA or ANDA approval, leaving it exposed to changes in regulatory requirements. vVardis also relies on Henry Schein for U.S. distribution, while larger dental technology groups could develop competing treatments. A dual-class structure is expected to leave the founders with 87% of voting power after the IPO, limiting public shareholders’ influence.

Investors will judge the revised offering on pricing, institutional demand and the company’s ability to convert rapid sales growth into profitability. vVardis could help establish a new category in preventive dentistry, but its market debut will be a meaningful sector signal only if public-market capital supports sustained commercial expansion.